20832 Federal Register / Vol. 77, No. 67 / Friday, April 6, 2012 / Notices 

Diagnosis Research; 93.395, Cancer 

Treatment Research; 93.396, Cancer Biology 

Research; 93.397, Cancer Centers Support; 

93.398, Cancer Research Manpower; 93.399, 

Cancer Control, National Institutes of Health, 

HHS) 

Dated: April 2, 2012. 

Anna P. Snouffer, 

Deputy Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2012–8353 Filed 4–5–12; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Center for Scientific Review; Notice of 

Closed Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App.), notice is 

hereby given of the following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Member 

Conflict: Synaptic Vesicles and 

Synaptogenesis. 

Date: April 18, 2012. 

Time: 1:30 p.m. to 3 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892, 

(Telephone Conference Call). 

Contact Person: Toby Behar, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 4136, 

MSC 7850, Bethesda, MD 20892, (301) 435– 

4433, behart@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Member 

Conflicts: Pain and Chemosensory 

Neuroscience. 

Date: April 25–26, 2012. 

Time: 8 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892, 

(Virtual Meeting). 

Contact Person: John Bishop, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 5182, 

MSC 7844, Bethesda, MD 20892, (301) 408– 

9664, bishopj@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Molecular 

Genetics Program Projects. 

Date: May 1, 2012. 

Time: 12 p.m. to 6 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892, 

(Virtual Meeting). 

Contact Person: Ronald Adkins, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 2206, 

MSC 7890, Bethesda, MD 20892, 301–435– 

4511, ronald.adkins@nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.306, Comparative Medicine; 

93.333, Clinical Research, 93.306, 93.333, 

93.337, 93.393–93.396, 93.837–93.844, 

93.846–93.878, 93.892, 93.893, National 

Institutes of Health, HHS) 

Dated: March 30, 2012. 

Jennifer S. Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2012–8352 Filed 4–5–12; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Substance Abuse and Mental Health 

Services Administration 

Current List of Laboratories and 

Instrumented Initial Testing Facilities 

Which Meet Minimum Standards To 

Engage in Urine Drug Testing for 

Federal Agencies 

AGENCY: Substance Abuse and Mental 

Health Services Administration, HHS. 

ACTION: Notice. 

SUMMARY: The Department of Health and 

Human Services (HHS) notifies Federal 

agencies of the Laboratories and 

Instrumented Initial Testing Facilities 

(IITF) currently certified to meet the 

standards of the Mandatory Guidelines 

for Federal Workplace Drug Testing 

Programs (Mandatory Guidelines). The 

Mandatory Guidelines were first 

published in the Federal Register on 

April 11, 1988 (53 FR 11970), and 

subsequently revised in the Federal 

Register on June 9, 1994 (59 FR 29908); 

September 30, 1997 (62 FR 51118); 

April 13, 2004 (69 FR 19644); November 

25, 2008 (73 FR 71858); December 10, 

2008 (73 FR 75122); and on April 30, 

2010 (75 FR 22809). 

A notice listing all currently certified 

Laboratories and Instrumented Initial 

Testing Facilities (IITF) is published in 

the Federal Register during the first 

week of each month. If any Laboratory/ 

IITF’s certification is suspended or 

revoked, the Laboratory/IITF will be 

omitted from subsequent lists until such 

time as it is restored to full certification 

under the Mandatory Guidelines. 

If any Laboratory/IITF has withdrawn 

from the HHS National Laboratory 

Certification Program (NLCP) during the 

past month, it will be listed at the end 

and will be omitted from the monthly 

listing thereafter. 

This notice is also available on the 

Internet at http:// 

www.workplace.samhsa.gov and http:// 

www.drugfreeworkplace.gov. 

FOR FURTHER INFORMATION CONTACT: Mrs. 

Giselle Hersh, Division of Workplace 

Programs, SAMHSA/CSAP, Room 2– 

1042, One Choke Cherry Road, 

Rockville, Maryland 20857; 240–276– 

2600 (voice), 240–276–2610 (fax). 

SUPPLEMENTARY INFORMATION: The 

Mandatory Guidelines were initially 

developed in accordance with Executive 

Order 12564 and section 503 of Public 

Law 100–71. The ‘‘Mandatory 

Guidelines for Federal Workplace Drug 

Testing Programs,’’ as amended in the 

revisions listed above, requires strict 

standards that Laboratories and 

Instrumented Initial Testing Facilities 

(IITF) must meet in order to conduct 

drug and specimen validity tests on 

urine specimens for Federal agencies. 

To become certified, an applicant 

Laboratory/IITF must undergo three 

rounds of performance testing plus an 

on-site inspection. To maintain that 

certification, a Laboratory/IITF must 

participate in a quarterly performance 

testing program plus undergo periodic, 

on-site inspections. 

Laboratories and Instrumented Initial 

Testing Facilities (IITF) in the applicant 

stage of certification are not to be 

considered as meeting the minimum 

requirements described in the HHS 

Mandatory Guidelines. A Laboratory/ 

IITF must have its letter of certification 

from HHS/SAMHSA (formerly: HHS/ 

NIDA) which attests that it has met 

minimum standards. 

In accordance with the Mandatory 

Guidelines dated November 25, 2008 

(73 FR 71858), the following 

Laboratories and Instrumented Initial 

Testing Facilities (IITF) meet the 

minimum standards to conduct drug 

and specimen validity tests on urine 

specimens: 

Instrumented Initial Testing Facilities 

(IITF): None. 

Laboratories: 

ACL Laboratories, 8901 W. Lincoln 

Ave., West Allis, WI 53227, 414–328– 

7840/800–877–7016 (Formerly: 

Bayshore Clinical Laboratory). 

ACM Medical Laboratory, Inc., 160 

Elmgrove Park, Rochester, NY 14624, 

585–429–2264. 

mstockstill on DSK4VPTVN1PROD with NOTICES

Federal Register / Vol. 77, No. 67 / Friday, April 6, 2012 / Notices 20833 

Advanced Toxicology Network, 3560 

Air Center Cove, Suite 101, Memphis, 

TN 38118, 901–794–5770/888–290– 

1150. 

Aegis Analytical Laboratories, 345 Hill 

Ave., Nashville, TN 37210, 615–255– 

2400, (Formerly: Aegis Sciences 

Corporation, Aegis Analytical 

Laboratories, Inc.). 

Alere Toxicology Services, 1111 Newton 

St., Gretna, LA 70053, 504–361–8989/ 

800–433–3823 (Formerly: Kroll 

Laboratory Specialists, Inc., 

Laboratory Specialists, Inc.). 

Alere Toxicology Services, 450 

Southlake Blvd., Richmond, VA 

23236, 804–378–9130 (Formerly: 

Kroll Laboratory Specialists, Inc., 

Scientific Testing Laboratories, Inc.; 

Kroll Scientific Testing Laboratories, 

Inc.). 

Baptist Medical Center-Toxicology 

Laboratory, 11401 I–30, Little Rock, 

AR 72209–7056, 501–202–2783, 

(Formerly: Forensic Toxicology 

Laboratory Baptist Medical Center). 

Clinical Reference Lab, 8433 Quivira 

Road, Lenexa, KS 66215–2802, 800– 

445–6917. 

Doctors Laboratory, Inc., 2906 Julia 

Drive, Valdosta, GA 31602, 229–671– 

2281. 

DrugScan, Inc., P.O. Box 2969, 1119 

Mearns Road, Warminster, PA 18974, 

215–674–9310. 

ElSohly Laboratories, Inc., 5 Industrial 

Park Drive, Oxford, MS 38655, 662– 

236–2609. 

Gamma-Dynacare Medical 

Laboratories*, A Division of the 

Gamma-Dynacare Laboratory 

Partnership, 245 Pall Mall Street, 

London, ONT, Canada N6A 1P4, 519– 

679–1630. 

Laboratory Corporation of America 

Holdings, 7207 N. Gessner Road, 

Houston, TX 77040, 713–856–8288/ 

800–800–2387. 

Laboratory Corporation of America 

Holdings, 69 First Ave., Raritan, NJ 

08869, 908–526–2400/800–437–4986 

(Formerly: Roche Biomedical 

Laboratories, Inc.). 

Laboratory Corporation of America 

Holdings, 1904 Alexander Drive, 

Research Triangle Park, NC 27709, 

919–572–6900/800–833–3984 

(Formerly: LabCorp Occupational 

Testing Services, Inc., CompuChem 

Laboratories, Inc.; CompuChem 

Laboratories, Inc., A Subsidiary of 

Roche Biomedical Laboratory; Roche 

CompuChem Laboratories, Inc., A 

Member of the Roche Group). 

Laboratory Corporation of America 

Holdings, 1120 Main Street, 

Southaven, MS 38671, 866–827–8042/ 

800–233–6339 (Formerly: LabCorp 

Occupational Testing Services, Inc.; 

MedExpress/National Laboratory 

Center). 

LabOne, Inc. d/b/a Quest Diagnostics, 

10101 Renner Blvd., Lenexa, KS 

66219, 913–888–3927/800–873–8845 

(Formerly: Quest Diagnostics 

Incorporated; LabOne, Inc.; Center for 

Laboratory Services, a Division of 

LabOne, Inc.). 

Maxxam Analytics*, 6740 Campobello 

Road, Mississauga, ON, Canada L5N 

2L8, 905–817–5700 (Formerly: 

Maxxam Analytics Inc., NOVAMANN 

(Ontario), Inc.). 

MedTox Laboratories, Inc., 402 W. 

County Road D, St. Paul, MN 55112, 

651–636–7466/800–832–3244. 

MetroLab-Legacy Laboratory Services, 

1225 NE 2nd Ave., Portland, OR 

97232, 503–413–5295/800–950–5295. 

Minneapolis Veterans Affairs Medical 

Center, Forensic Toxicology 

Laboratory, 1 Veterans Drive, 

Minneapolis, MN 55417, 612–725– 

2088. 

National Toxicology Laboratories, Inc., 

1100 California Ave., Bakersfield, CA 

93304, 661–322–4250/800–350–3515. 

One Source Toxicology Laboratory, Inc., 

1213 Genoa-Red Bluff, Pasadena, TX 

77504, 888–747–3774 (Formerly: 

University of Texas Medical Branch, 

Clinical Chemistry Division; UTMB 

Pathology-Toxicology Laboratory). 

Pacific Toxicology Laboratories, 9348 

DeSoto Ave., Chatsworth, CA 91311, 

800–328–6942 (Formerly: Centinela 

Hospital Airport Toxicology 

Laboratory). 

Pathology Associates Medical 

Laboratories, 110 West Cliff Dr., 

Spokane, WA 99204, 509–755–8991/ 

800–541–7891x7. 

Phamatech, Inc., 10151 Barnes Canyon 

Road, San Diego, CA 92121, 858–643– 

5555. 

Quest Diagnostics Incorporated, 5601 

Office Blvd., Albuquerque, NM 87109, 

505–727–6300/800–999–5227 

(Formerly: S.E.D. Medical 

Laboratories). 

Quest Diagnostics Incorporated, 1777 

Montreal Circle, Tucker, GA 30084, 

800–729–6432 (Formerly: SmithKline 

Beecham Clinical Laboratories; 

SmithKline Bio-Science Laboratories). 

Quest Diagnostics Incorporated, 400 

Egypt Road, Norristown, PA 19403, 

610–631–4600/877–642–2216 

(Formerly: SmithKline Beecham 

Clinical Laboratories; SmithKline BioScience Laboratories). 

Quest Diagnostics Incorporated, 8401 

Fallbrook Ave., West Hills, CA 91304, 

800–877–2520 (Formerly: SmithKline 

Beecham Clinical Laboratories). 

South Bend Medical Foundation, Inc., 

530 N. Lafayette Blvd., South Bend, 

IN 46601, 574–234–4176 x1276. 

Southwest Laboratories, 4625 E. Cotton 

Center Boulevard, Suite 177, Phoenix, 

AZ 85040, 602–438–8507/800–279– 

0027. 

STERLING Reference Laboratories, 2617 

East L Street, Tacoma, Washington 

98421, 800–442–0438. 

Toxicology & Drug Monitoring 

Laboratory, University of Missouri 

Hospital & Clinics, 301 Business Loop 

70 West, Suite 208, Columbia, MO 

65203, 573–882–1273. 

US Army Forensic Toxicology Drug 

Testing Laboratory, 2490 Wilson St., 

Fort George G. Meade, MD 20755– 

5235, 301–677–7085. 

The following laboratory voluntarily 

withdrew from the National Laboratory 

Certification Program on March 31, 

2012: 

St. Anthony Hospital Toxicology 

Laboratory, 1000 N. Lee St., 

Oklahoma City, OK 73101, 405–272– 

7052. 

The following laboratory voluntarily 

withdrew from the National Laboratory 

Certification Program on March 31, 

2012: 

Toxicology Testing Service, Inc., 5426 

NW. 79th Ave., Miami, FL 33166, 

305–593–2260. 

* The Standards Council of Canada 

(SCC) voted to end its Laboratory 

Accreditation Program for Substance 

Abuse (LAPSA) effective May 12, 1998. 

Laboratories certified through that 

program were accredited to conduct 

forensic urine drug testing as required 

by U.S. Department of Transportation 

(DOT) regulations. As of that date, the 

certification of those accredited 

Canadian laboratories will continue 

under DOT authority. The responsibility 

for conducting quarterly performance 

testing plus periodic on-site inspections 

of those LAPSA-accredited laboratories 

was transferred to the U.S. HHS, with 

the HHS’ NLCP contractor continuing to 

have an active role in the performance 

testing and laboratory inspection 

processes. Other Canadian laboratories 

wishing to be considered for the NLCP 

may apply directly to the NLCP 

contractor just as U.S. laboratories do. 

Upon finding a Canadian laboratory to 

be qualified, HHS will recommend that 

DOT certify the laboratory (Federal 

Register, July 16, 1996) as meeting the 

minimum standards of the Mandatory 

Guidelines published in the Federal 

Register on April 30, 2010 (75 FR 

22809). After receiving DOT 

mstockstill on DSK4VPTVN1PROD with NOTICES

20834 Federal Register / Vol. 77, No. 67 / Friday, April 6, 2012 / Notices 

certification, the laboratory will be 

included in the monthly list of HHScertified laboratories and participate in 

the NLCP certification maintenance 

program. 

Janine Denis Cook, 

Chemist, Division of Workplace Programs, 

Center for Substance Abuse Prevention, 

SAMHSA. 

[FR Doc. 2012–8236 Filed 4–5–12; 8:45 am] 

BILLING CODE 4160–20–P 

DEPARTMENT OF HOMELAND 

SECURITY 

Coast Guard 

[Docket No. USCG–2011–0138] 

Merchant Mariner Medical Advisory 

Committee 

AGENCY: Coast Guard, DHS. 

ACTION: Notice of Federal Advisory 

Committee Meeting. 

SUMMARY: The Merchant Mariner 

Medical Advisory Committee 

(MMMAC) will meet on May 8–9, 2012 

to discuss matters relating to medical 

certification determinations for issuance 

of merchant mariner credentials, 

medical standards and guidelines for 

physical qualifications of operators of 

commercial vessels, medical examiner 

education, and medical research. The 

meeting will be open to the public. 

DATES: MMMAC will meet on Tuesday, 

May 8, and Wednesday, May 9, 2012 

from 8 a.m. to 5:30 p.m. Please note that 

the meeting may close early if the 

committee has completed its business. 

ADDRESSES: The meeting will be held at 

the National Maritime Center (NMC), 

3rd floor conference room, 100 Forbes 

Drive, Martinsburg, West Virginia 

25404. 

Please be advised that in order to gain 

admittance to the NMC building, you 

must provide identification in the form 

of a government-issued picture 

identification card. If you plan to attend, 

please notify the individual listed in 

FOR FURTHER INFORMATION CONTACT, no 

later than April 20, 2012 so that 

administrative access into the NMC 

building can be processed prior to 

arrival. 

For information on facilities or 

services for individuals with disabilities 

or to request special assistance at the 

meeting, contact LT Dylan McCall, the 

ADFO, 202–372–1128 as soon as 

possible. 

To facilitate public participation, we 

are inviting public comment on the 

issues to be considered by the 

committee as listed in the ‘‘Agenda’’ 

section below. Comments must be 

submitted in writing to the Coast Guard 

on or before April 20, 2012 and must be 

identified by USCG–2011–0138 and 

may be submitted by one of the 

following methods: 

• Federal eRulemaking Portal: http:// 

www.regulations.gov. Follow the 

instructions for submitting comments 

(preferred method to avoid delays in 

processing). 

• Fax: 202–372–1246. 

• Mail: Docket Management Facility 

(M–30), U.S. Department of 

Transportation, West Building Ground 

Floor, Room W12–140, 1200 New Jersey 

Avenue SE., Washington, DC 20590– 

0001. 

• Hand delivery: Same as mail 

address above, between 9 a.m. and 5 

p.m., Monday through Friday, except 

Federal Holidays. The telephone 

number is 202–366–9329. 

Instructions: All submissions received 

must include the words ‘‘Department of 

Homeland Security’’ and the docket 

number for this action. Comments 

received will be posted without 

alteration at http://www.regulations.gov, 

including any personal information 

provided. You may review a Privacy Act 

notice regarding our public dockets in 

the January 17, 2008, issue of the 

Federal Register (73 FR 3316). If you 

would like a copy of your material 

distributed to each member of the 

committee in advance of the meeting, 

please submit 15 copies to the ADFO no 

later than April 20, 2012. 

Docket: For access to the docket to 

read background documents or 

comments related to this notice, go to 

http://www.regulations.gov. 

A public comment period will be held 

on May 8, 2012, from 9:20 a.m. to 9:30 

a.m., and May 9, 2012 from 5 p.m. to 

5:10 p.m. Speakers are requested to 

limit their comments to 3 minutes. 

Please note that the public comment 

period may end before the time 

indicated, following the last call for 

comments. Additionally, public 

comment will be sought throughout the 

meeting as specific tasks and issues are 

discussed by the committee. Contact the 

individual listed below to register as a 

speaker. 

FOR FURTHER INFORMATION CONTACT: 

Lieutenant Dylan McCall, the MMMAC 

ADFO, at telephone 202–372–1128 or 

email Dylan.k.mccall@uscg.mil. If you 

have questions on viewing or submitting 

material to the docket, call Renee V. 

Wright, Program Manager, Docket 

Operations, telephone 202–366–9826. 

SUPPLEMENTARY INFORMATION: Notice of 

this meeting is given under the Federal 

Advisory Committee Act, 5 U.S.C. App. 

(Pub. L. 92–463). The MMMAC is 

authorized by section 210 of the Coast 

Guard Authorization Act of 2010 (Pub. 

L. 111–281) and the committee’s 

purpose is to advise the Secretary on 

matters related to medical certification 

determinations for issuance of merchant 

mariner credentials; medical standards 

and guidelines for the physical 

qualifications of operators of 

commercial vessels; medical examiner 

education; and medical research. 

Agenda: 

Day 1 

(1) Opening comments by Designated 

Federal Officer (DFO), Captain E. P. 

Christensen. 

(2) Remarks from National Maritime 

Center Leadership. 

(3) Introduction and swearing in of 

the new members. 

(4) Designation of the Chair and ViceChair. 

(5) Review of Last Meeting’s Minutes. 

(6) Public Comments. 

(7) Working Groups addressing the 

following task statements may meet to 

deliberate— 

(a) Task Statement 1, Revising 

Navigation and Vessel Inspection 

Circular (NVIC) 04–08. The NVIC can be 

found at http://www.uscg.mil/hq/cg5/ 

nvic/. Medical and Physical Guidelines 

for Merchant Mariner Credentials. 

(b) Task Statement 2, top medical 

conditions leading to denial of mariner 

credentials. 

(c) Task Statement 4, Revising the 

CG–719K Medical Evaluation Report 

Form for mariner physicals. The form 

can be found at http://www.uscg.mil/ 

nmc. 

(d) Task Statement 5, Creating 

medical expert panels for the top 

medical conditions. 

(e) Task Statement 6, Developing 

designated medical examiner program. 

Day 2 

(1) Working Group Discussions 

continued from Day 1. 

(2) By mid-afternoon, the Working 

Groups will report, and if applicable, 

make recommendations for the full 

committee to consider for presentation 

to the Coast Guard. Official action on 

these recommendations may be taken on 

this date. The public will have an 

opportunity to speak during the 

Working Groups Report. 

(3) General public comments/ 

presentations. 

(4) Closing remarks/plans for next 

meeting. 

mstockstill on DSK4VPTVN1PROD with NOTICES